Kampanjeplan Sandoz Group AG
Avansert tidsplan
Enkel graf
Om selskapet
Sandoz Group AG develops, manufactures, and markets generic pharmaceuticals and biosimilars worldwide. It develops, manufactures, and markets finished dosage forms of small molecule pharmaceuticals to third parties. It also provides protein- or other biotechnology-based products, including biosimilars; and biotechnology manufacturing services; and anti-infectives, such as active pharmaceutical ingredients and intermediates primarily antibiotics. The company was founded in 1886 and is headquartered in Rotkreuz, Switzerland.
| Industry |
Pharmaceuticals |
| Sector |
Health Care |
| Валюта |
usd |
| Валюта отчета |
usd |
| Сайт |
https://www.sandoz.com
|
| Цена ао |
34.6 |
| Prisendring per dag: |
0% (41.31) |
| Prisendring per uke: |
-0.709% (41.605) |
| Prisendring per måned: |
-1.88% (42.1) |
| Prisendring over 3 måneder: |
+9.52% (37.72) |
| Prisendring over seks måneder: |
+40.83% (29.333) |
| Prisendring siden begynnelsen av året: |
+45.46% (28.4) |
|
|
Undervurdering
| Navn |
Betydning |
Karakter |
| P/S |
0 |
0 |
| P/BV |
0 |
0 |
| P/E |
0 |
0 |
| EV/EBITDA |
0 |
0 |
| Total: |
|
2.5 |
|
Effektivitet
| Navn |
Betydning |
Karakter |
| ROA, % |
0 |
0 |
| ROE, % |
0 |
0 |
| Total: |
|
0 |
|
|
|
Utbytte
| Navn |
Betydning |
Karakter |
| Div yield, % |
0 |
0 |
| DSI |
0 |
0 |
| Total: |
|
0 |
|
Plikt
| Navn |
Betydning |
Karakter |
| Debt/EBITDA |
0 |
10 |
| Total: |
|
10 |
|
Vekstimpuls
| Navn |
Betydning |
Karakter |
| Lønnsomhet Revenue, % |
7.23 |
1 |
| Lønnsomhet Ebitda, % |
0 |
0 |
| Lønnsomhet EPS, % |
0 |
0 |
| Total: |
|
0.2 |
|
| Utbytte, % |
Utbytte |
Basert på resultatene fra perioden |
Kjøp før |
Utløpsdato for registeret |
Utbetaling før |
| 0.87% |
0.3 |
I кв. 2024 |
01.05.2024 | 03.05.2024 |
20.05.2024 |
| Veileder |
Stillingstittel |
Betaling |
Fødselsår |
| Mr. Richard Saynor |
Chief Executive Officer |
N/A |
1967 (57 år) |
| Mr. Asaf Gal |
Chief Technology Officer |
N/A |
1969 (55 år) |
| Ms. Karen M. King |
Head Global Investor Relations |
N/A |
|
| Ms. Ingrid Sollerer |
General Counsel & Chief Compliance Officer |
N/A |
1974 (50 år) |
| Ms. Tripti Jha |
Chief People Officer |
N/A |
1977 (47 år) |
| Mr. Francisco Ballester |
President of International |
N/A |
1961 (63 år) |
| Mr. Pierre Bourdage |
Chief Commercial Officer |
N/A |
1979 (45 år) |
| Dr. Glenn A. Gerecke Ph.D. |
Chief Manufacturing & Supply Officer |
N/A |
1959 (65 år) |
| Mr. Remco J. Steenbergen |
Chief Financial Officer |
|
1968 (56 år) |
| Ms. Claire D'Abreu-Hayling |
Chief Scientific Officer |
|
1964 (60 år) |
